IART
Integra LifeSciences Holdings Corporation
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Sell
-35/100
Last price
13.30
▲ 0.01 (0.11%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
13.20
Prev close
13.29
Day high
13.51
Day low
12.88
Volume
1.37M
Market cap
$1.04B
P/E (TTM)
—
52W range
8.70 – 20.49
Day trading desk
Gap from prior close
-0.68%
Prior close 13.29
VWAP
13.28
+0.19% from price
Relative volume
2.69×
Unusually busy
Session range
16.58%
12.00 – 13.99
Position in range
66%
Mid range
ATR (14D)
0.90
6.76% of price
Prior day high
13.49
PDH
Prior day low
12.35
PDL
Bid / ask spread
—
Quote not published
Session volume
2.41M
Avg 897.40K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-19.95%
-21.9%
1M
-20.33%
-21.5%
3M
-23.01%
-27.5%
6M
+42.77%
+24.6%
YTD
+7.25%
-7.0%
1Y
-10.00%
-26.4%
3Y
-65.12%
-147.4%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
11 more panels on IART open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
11.15M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| May 7, 26 | HILL BARBARA BENTON Director |
STOCK | 24.34K | $0 | Direct |
| Mar 11, 26 | SINGH HARVINDER Officer |
— | 20.14K | — | Direct |
| Jan 6, 26 | POUL MOJDEH Chief Executive Officer |
— | 1.39K | — | Direct |
| Nov 5, 25 | GRAVES JEFFREY A. Director |
BUY | 9.00K | $102.15K | Direct |
| Oct 10, 25 | SINGH HARVINDER Officer |
— | 11.96K | — | Direct |
| May 9, 25 | BRADLEY KEITH Director |
STOCK | 19.59K | $0 | Direct |
| May 9, 25 | ESSIG STUART PH.D. Officer and Director |
STOCK | 31.84K | $0 | Direct |
| May 9, 25 | HILL BARBARA BENTON Director |
STOCK | 26.53K | $0 | Direct |
| May 9, 25 | SCHADE CHRISTIAN S Director |
STOCK | 26.53K | $0 | Direct |
| May 9, 25 | GRAVES JEFFREY A. Director |
STOCK | 19.59K | $0 | Direct |
| May 9, 25 | CLAY SHAUNDRA Director |
STOCK | 19.59K | $0 | Direct |
| May 9, 25 | LO RENEE WONLAI Director |
STOCK | 19.59K | $0 | Direct |
| Mar 11, 25 | SINGH HARVINDER Officer |
— | 2.36K | — | Direct |
| Mar 11, 25 | DAVIS ROBERT T JR Officer |
STOCK | 12.43K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BRADLEY KEITH |
Director | 89.14K | Stock Award(Grant) |
CLAY SHAUNDRA |
Director | 41.52K | Stock Award(Grant) |
DAVIS ROBERT T JR |
Officer | 75.56K | Stock Award(Grant) |
ESSIG STUART PH.D. |
Officer and Director | 1.79M | Stock Award(Grant) |
GRAVES JEFFREY A. |
Director | 41.09K | Purchase |
HILL BARBARA BENTON |
Director | 187.54K | Stock Award(Grant) |
KNIGHT LEA DANIELS |
Chief Financial Officer | 61.14K | Stock Award(Grant) |
MCBREEN MICHAEL J |
Officer | 70.34K | Stock Award(Grant) |
SCHADE CHRISTIAN S |
Director | 90.03K | Stock Award(Grant) |
SCHWARTZ ERIC IAN |
Officer | 59.51K | Sale |
Fundamentals
Market cap$1.04B
Enterprise value$2.81B
Revenue (TTM)$1.65B
Gross profit$937.07M
EBITDA$316.92M
Net income$-7.24M
EPS (TTM)$-0.09
Free cash flow$94.40M
Total cash$274.08M
Total debt$2.05B
Book value / share$13.42
Shares outstanding77.77M
Float58.65M
Short % of float12.07%
Dividend yield0.00%
Beta (5Y)1.21
Valuation & profitability ratios
Trailing P/E—
Forward P/E5.13
PEG ratio0.67
Price / sales—
Price / book0.99
EV / revenue1.71
EV / EBITDA8.87
Gross margin56.87%
Operating margin9.62%
Profit margin-0.44%
Return on equity-0.70%
Return on assets2.83%
Debt / equity196.49
Current ratio3.60
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $1.64B | $1.61B | $1.54B | $1.56B | +1.5% |
| Operating revenue | $1.64B | $1.61B | $1.54B | $1.56B | +1.5% |
| Cost of revenue | $803.63M | $728.47M | $656.84M | $587.36M | +10.3% |
| Gross profit | $831.62M | $882.06M | $884.74M | $970.31M | -5.7% |
| Research & development | $98.97M | $115.38M | $104.19M | $101.19M | -14.2% |
| Selling, general & admin | $699.70M | $716.98M | $656.64M | $616.32M | -2.4% |
| Total operating expense | $813.63M | $853.65M | $773.21M | $731.39M | -4.7% |
| Operating income | $18.00M | $28.41M | $111.53M | $238.92M | -36.7% |
| Net interest income | -$67.78M | -$50.59M | -$34.17M | -$37.68M | -34.0% |
| Pre-tax income | -$563.50M | -$18.24M | $81.07M | $213.89M | -2,989.9% |
| Tax provision | -$47.03M | -$11.29M | $13.33M | $33.34M | -316.4% |
| Net income | -$516.47M | -$6.94M | $67.74M | $180.55M | -7,337.7% |
| Net income to common | -$516.47M | -$6.94M | $67.74M | $180.55M | -7,337.7% |
| Basic EPS | -6.63 | -0.09 | 0.87 | 2.16 | -7,268.7% |
| Diluted EPS | -6.74 | -0.09 | 0.84 | 2.16 | -7,388.9% |
| EBIT | -$477.25M | $52.40M | $132.45M | $263.49M | -1,010.9% |
| EBITDA | -$325.42M | $193.29M | $255.96M | $381.79M | -268.4% |
| Basic shares | 77.89M | 77.16M | 78.17M | 83.59M | +0.9% |
| Diluted shares | 77.89M | 77.16M | 80.34M | 83.59M | +0.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $235.05M | $246.38M | $276.40M | $456.66M | -4.6% |
| Cash & short-term investments | $263.74M | $273.57M | $309.10M | $456.66M | -3.6% |
| Accounts receivable | $278.85M | $272.37M | $259.33M | $263.46M | +2.4% |
| Inventory | $492.74M | $429.09M | $389.61M | $324.58M | +14.8% |
| Total current assets | $1.16B | $1.08B | $1.06B | $1.16B | +7.2% |
| Property, plant & equipment | $584.90M | $549.76M | $496.38M | $459.59M | +6.4% |
| Goodwill & intangibles | $1.75B | $2.30B | $2.12B | $2.17B | -24.1% |
| Total assets | $3.60B | $4.04B | $3.78B | $3.89B | -10.8% |
| Total current liabilities | $455.98M | $922.13M | $306.98M | $320.91M | -50.6% |
| Current debt | $126.55M | $607.08M | $14.53M | $38.13M | -79.2% |
| Long-term debt | $1.73B | $1.20B | $1.49B | $1.41B | +44.6% |
| Total debt | $2.03B | $1.98B | $1.68B | $1.62B | +2.4% |
| Total liabilities | $2.56B | $2.49B | $2.19B | $2.09B | +2.7% |
| Retained earnings | $423.44M | $939.91M | $946.86M | $879.12M | -54.9% |
| Shareholder equity | $1.04B | $1.55B | $1.59B | $1.80B | -32.5% |
| Working capital | $703.56M | $159.56M | $751.06M | $840.59M | +341.0% |
| Net tangible assets | -$706.36M | -$759.26M | -$535.41M | -$361.09M | +7.0% |
| Shares issued | 92.29M | 91.61M | 90.92M | 90.48M | +0.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$516.47M | -$6.94M | $67.74M | $180.55M | -7,337.7% |
| Depreciation & amortisation | $151.83M | $140.89M | $123.51M | $118.30M | +7.8% |
| Stock-based compensation | $18.58M | $24.38M | $20.14M | $27.73M | -23.8% |
| Change in working capital | -$33.74M | -$31.01M | -$81.57M | -$39.42M | -8.8% |
| Operating cash flow | $50.38M | $129.38M | $139.96M | $264.47M | -61.1% |
| Capital expenditure | -$95.64M | -$114.37M | -$66.86M | -$47.09M | +16.4% |
| Investing cash flow | -$108.06M | -$390.81M | -$94.18M | -$58.58M | +72.3% |
| Share buybacks | -$221.00K | -$52.47M | -$275.00M | -$125.00M | +99.6% |
| Financing cash flow | $28.34M | $237.86M | -$229.93M | -$251.95M | -88.1% |
| Free cash flow | -$45.25M | $15.01M | $73.09M | $217.38M | -401.5% |
| End cash position | $235.05M | $246.38M | $276.40M | $456.66M | -4.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $418.76M | $391.92M | $434.93M | $402.06M | $415.61M | +6.8% |
| Operating revenue | $418.76M | $391.92M | $434.93M | $402.06M | $415.61M | +6.8% |
| Cost of revenue | $199.02M | $174.94M | $214.06M | $195.07M | $206.27M | +13.8% |
| Gross profit | $219.74M | $216.98M | $220.87M | $206.99M | $209.33M | +1.3% |
| Research & development | $24.25M | $23.50M | $24.79M | $22.46M | $27.00M | +3.2% |
| Selling, general & admin | $172.44M | $178.24M | $169.27M | $169.05M | $179.89M | -3.3% |
| Total operating expense | $200.46M | — | — | — | — | — |
| Operating income | $19.29M | $11.47M | $23.04M | $11.76M | -$1.31M | +68.1% |
| Net interest income | -$18.73M | -$18.36M | -$19.31M | -$17.74M | -$16.33M | -2.0% |
| Pre-tax income | $4.74M | -$2.41M | $4.31M | -$6.82M | -$530.95M | +296.9% |
| Tax provision | $262.00K | $2.21M | $6.01M | -$1.42M | -$46.88M | -88.1% |
| Net income | $4.48M | -$4.62M | -$1.70M | -$5.40M | -$484.07M | +197.1% |
| Net income to common | $4.48M | -$4.62M | -$1.70M | -$5.40M | -$484.07M | +197.1% |
| Basic EPS | 0.06 | -0.06 | -0.02 | -0.07 | -6.21 | +196.0% |
| Diluted EPS | 0.06 | -0.06 | -0.02 | -0.07 | -6.31 | +196.0% |
| EBIT | $27.74M | $20.06M | $27.98M | $15.90M | -$509.91M | +38.3% |
| EBITDA | $65.87M | $58.49M | $66.41M | $54.42M | -$472.22M | +12.6% |
| Basic shares | 77.78M | 76.95M | 77.89M | 76.75M | 77.92M | +1.1% |
| Diluted shares | 78.17M | 76.95M | 77.89M | 77.20M | 77.92M | +1.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $214.41M | $236.81M | $235.05M | $232.19M | $217.91M | -9.5% |
| Cash & short-term investments | $274.08M | $265.50M | $263.74M | $267.88M | $253.61M | +3.2% |
| Accounts receivable | $267.19M | $264.41M | $278.85M | $262.16M | $284.51M | +1.0% |
| Inventory | $492.00M | $495.04M | $492.74M | $489.11M | $465.13M | -0.6% |
| Total current assets | $1.19B | $1.17B | $1.16B | $1.14B | $1.14B | +1.7% |
| Property, plant & equipment | $583.29M | $584.08M | $584.90M | $575.55M | $571.39M | -0.1% |
| Goodwill & intangibles | $1.69B | $1.72B | $1.75B | $1.78B | $1.80B | -1.9% |
| Total assets | $3.56B | $3.58B | $3.60B | $3.65B | $3.67B | -0.4% |
| Total current liabilities | $330.88M | $346.85M | $455.98M | $364.05M | $929.81M | -4.6% |
| Current debt | $43.59M | $38.75M | $126.55M | $38.75M | $613.38M | +12.5% |
| Long-term debt | $1.83B | $1.83B | $1.73B | $1.79B | $1.23B | +0.1% |
| Total debt | $2.05B | $2.04B | $2.03B | $2.01B | $2.01B | +0.5% |
| Total liabilities | $2.52B | $2.54B | $2.56B | $2.61B | $2.63B | -0.6% |
| Retained earnings | $423.31M | $418.82M | $423.44M | $425.14M | $430.55M | +1.1% |
| Shareholder equity | $1.04B | $1.04B | $1.04B | $1.04B | $1.04B | +0.1% |
| Working capital | $860.60M | $825.17M | $703.56M | $779.53M | $213.02M | +4.3% |
| Net tangible assets | -$643.31M | -$676.19M | -$706.36M | -$737.77M | -$765.85M | +4.9% |
| Shares issued | 77.78M | 92.17M | 92.29M | 92.25M | 92.34M | -15.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $4.48M | -$4.62M | -$1.70M | -$5.40M | -$484.07M | +197.1% |
| Depreciation & amortisation | $38.13M | $38.43M | $38.43M | $38.52M | $37.69M | -0.8% |
| Stock-based compensation | $5.84M | $5.17M | $5.84M | $5.58M | $5.29M | +13.1% |
| Change in working capital | -$26.13M | — | — | — | — | — |
| Operating cash flow | $22.80M | $9.80M | $11.82M | $40.91M | $8.92M | +132.6% |
| Capital expenditure | -$12.31M | -$14.85M | -$31.42M | -$15.16M | -$20.15M | +17.1% |
| Investing cash flow | -$43.28M | -$14.85M | -$34.91M | -$15.59M | -$21.65M | -191.5% |
| Share buybacks | — | — | $0 | $0 | — | — |
| Financing cash flow | -$818.00K | $8.30M | $24.34M | -$10.24M | -$21.14M | -109.9% |
| Free cash flow | $10.49M | -$5.04M | -$19.60M | $25.75M | -$11.23M | +308.0% |
| End cash position | $214.41M | $236.81M | $235.05M | $232.19M | $217.91M | -9.5% |
Options analytics
Put / call volume
2.75
Put-heavy session
Put / call open interest
2.03
Positioning, not flow
Max pain
17.50
+31.4% from spot
ATM implied vol
67.4%
Nearest strike to spot
Skew (10% OTM)
-20.7%
Calls bid over puts
Call volume
12
Contracts, this expiry
Put volume
33
Contracts, this expiry
Heaviest call OI
15.00
20 contracts
Heaviest put OI
17.50
31 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.48 | 0.56 | +16.5% |
| Mar 2026 | 0.40 | 0.54 | +33.4% |
| Dec 2025 | 0.80 | 0.83 | +3.7% |
| Sep 2025 | 0.43 | 0.54 | +24.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.56 | 9 | $412.80M | +2.7% |
| Next quarter | 0.76 | 9 | $435.91M | +0.2% |
| Current year | 2.40 | 7 | $1.66B | +1.7% |
| Next year | 2.59 | 11 | $1.72B | +3.4% |
Analyst targets & ownership
Mean target$18.38
High target$27.00
Low target$14.00
Implied upside38.12%
Analyst count8
ConsensusHOLD
Strong buy / Buy1 / 2
Hold6
Sell / Strong sell0 / 2
Held by insiders14.33%
Held by institutions98.67%
Institutions holding299
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
15.21
-12.53% from price
SMA 20
15.44
-13.72% from price
SMA 50
16.49
-19.24% from price
SMA 100
16.92
-21.35% from price
SMA 200
14.05
-5.22% from price
EMA 12
14.92
-10.80% from price
EMA 26
15.60
-14.72% from price
EMA 50
16.11
-17.44% from price
RSI (14)
32.4
Neutral
MACD (12,26,9)
-0.68
Hist -0.25
ATR (14)
0.90
6.75% of price
Realised vol 30D
76.8%
Annualised
Bollinger upper
17.55
20, 2σ
Bollinger lower
13.32
20, 2σ
50 / 200 cross
Golden
16.49 vs 14.05
Trend bias
Below 200
-5.22%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.80
More volatile than market
Correlation to SPY
0.37
Loosely linked
Realised vol 30D
76.8%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-44.8%
Peak to trough
Max drawdown 5Y
-87.8%
Peak to trough
ATR 14
0.90
6.75% of price
Beta (reported)
1.21
5Y monthly, from filing
Short interest
Shares short
6.81M
Prior 6.74M
Change vs prior
+0.9%
Shorts adding
% of float
12.07%
Elevated
% of shares out
8.75%
Against total outstanding
Days to cover
9.8
Crowded exit
Float
58.65M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 5, 26 | Citigroup | MAINTAINED | Neutral | Neutral |
| Oct 5, 26 | BMO Capital | MAINTAINED | Market Perform | Market Perform |
| Jul 30, 26 | Wells Fargo | MAINTAINED | Equal-Weight | Equal-Weight |
| Jul 28, 26 | UBS | INITIATED | — | Neutral |
| Jul 16, 26 | Truist Securities | MAINTAINED | Hold | Hold |
| Jul 9, 26 | BMO Capital | INITIATED | — | Market Perform |
| Jul 8, 26 | Citigroup | MAINTAINED | Neutral | Neutral |
| May 28, 26 | Citigroup | UPGRADE | Sell | Neutral |
| May 6, 26 | Citigroup | MAINTAINED | Sell | Sell |
| May 6, 26 | Wells Fargo | MAINTAINED | Equal-Weight | Equal-Weight |
| Apr 15, 26 | Truist Securities | MAINTAINED | Hold | Hold |
| Apr 15, 26 | Argus Research | DOWNGRADE | Buy | Hold |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split2:1
Split dateJan 4, 2017
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-10-02
Corporate Changes & Voting Matters
8-K · 2026-09-08
Periodic Financial Reports
10-Q · 2026-07-29
Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)
SD · 2026-05-29
Corporate Changes & Voting Matters
8-K · 2026-05-08
Periodic Financial Reports
10-Q · 2026-05-05
Corporate Changes & Voting Matters
8-K · 2026-04-15
Proxy Statements
DEF 14A · 2026-04-06
Headlines
Integra LifeSciences to Host Third Quarter 2026 Financial Results Conference Call on October 21, 2026
GlobeNewswire · 14h ago
Nasdaq Hits Fresh Highs While Dow Slips and Small Caps Struggle for Direction
CNW Group · 1d ago
3 Small-Cap Stocks We Approach with Caution
StockStory · 2d ago
Nasdaq Hits Fresh Ground on Chip and Software Strength as Dow, Small Caps Lag for the Week
CNW Group · 4d ago
Why Integra LifeSciences (IART) Stock Is Nosediving
StockStory · 4d ago
Sector Update: Healthcare Stocks Steady Late Afternoon
MT Newswires · 4d ago
Sector Update: Healthcare Stocks Softer in Afternoon Trading
MT Newswires · 4d ago
Integra LifeSciences lowers revenue and earnings outlook for 2026
Proactive · 5d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.